{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:38:22Z","timestamp":1794109102885,"version":"4.8.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.xkme.2022.100504","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T12:55:48Z","timestamp":1656248148000},"page":"100504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Serum Amyloid A Protein\u2013Associated Kidney Disease: Presentation, Diagnosis, and Management"],"prefix":"10.1016","volume":"4","author":[{"given":"Jordan","family":"Thorne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurette","family":"Geldenhuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigan","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Vinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Tennankore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xkme.2022.100504_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ckj\/sfu021","article-title":"Amyloid nephropathy","volume":"7","author":"Khalighi","year":"2014","journal-title":"Clin Kidney J"},{"issue":"23","key":"10.1016\/j.xkme.2022.100504_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2022.100504_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","article-title":"Systemic AA amyloidosis: epidemiology, diagnosis, and management","volume":"6","author":"Real de As\u00faa","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2141.2001.02999.x","article-title":"Amyloidosis: a convoluted story","volume":"114","author":"Kyle","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.xkme.2022.100504_bib5","series-title":"Amyloidosis \u2013History and Perspectives","article-title":"An historical overview of the amyloidoses","author":"Harrison","year":"2021"},{"key":"10.1016\/j.xkme.2022.100504_bib6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2019.1693359","article-title":"Causes of AA amyloidosis: a systematic review","volume":"27","author":"Brunger","year":"2020","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.xkme.2022.100504_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/msj.21342","article-title":"AA amyloidosis: Mount Sinai experience, 1997-2012","volume":"79","author":"Bunker","year":"2012","journal-title":"Mt Sinai J Med"},{"issue":"8","key":"10.1016\/j.xkme.2022.100504_bib10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/ndt\/gfh890","article-title":"Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients","volume":"20","author":"Ensari","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2022.100504_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13966","article-title":"Infections and AA amyloidosis: an overview","volume":"75","author":"Deshayes","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"17","key":"10.1016\/j.xkme.2022.100504_bib12","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/archinte.166.17.1805","article-title":"Amyloidosis and the heart: a comprehensive review","volume":"166","author":"Shah","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000508022","article-title":"Confirming the diagnosis of amyloidosis","volume":"143","author":"Wisniowski","year":"2020","journal-title":"Acta Haematol"},{"issue":"12","key":"10.1016\/j.xkme.2022.100504_bib14","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.xkme.2022.100504_bib15","first-page":"1482","article-title":"Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis","volume":"33","author":"Uda","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.xkme.2022.100504_bib16","series-title":"Amyloidosis. IntechOpen","article-title":"Diagnosis and treatment of AA amyloidosis with rheumatoid arthritis: state of the art","author":"Kuroda","year":"2013"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1440-1827.2001.01188.x","article-title":"Glomerular crescents in renal amyloidosis: an epiphenomenon or distinct pathology?","volume":"51","author":"Nagata","year":"2001","journal-title":"Pathol Int"},{"issue":"7","key":"10.1016\/j.xkme.2022.100504_bib18","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1093\/rheumatology\/keaa772","article-title":"Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever","volume":"60","author":"Kukuy","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.xkme.2022.100504_bib19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/labinvest.3700161","article-title":"AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells","volume":"84","author":"Keeling","year":"2004","journal-title":"Lab Invest"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.xkme.2022.100504_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","article-title":"AA amyloidosis: pathogenesis and targeted therapy","volume":"10","author":"Westermark","year":"2015","journal-title":"Annu Rev Pathol"},{"issue":"9275","key":"10.1016\/j.xkme.2022.100504_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib23","first-page":"371","article-title":"Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis","volume":"75","author":"Migita","year":"1996","journal-title":"Lab Invest"},{"key":"10.1016\/j.xkme.2022.100504_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.631299","article-title":"Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker","volume":"11","author":"Sori\u0107 Hosman","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib25","doi-asserted-by":"crossref","first-page":"355.e15","DOI":"10.1016\/j.amjmed.2005.08.043","article-title":"Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis","volume":"119","author":"Hazenberg","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.xkme.2022.100504_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/bmb\/ldt021","article-title":"Imaging in systemic amyloidosis","volume":"107","author":"Sachchithanantham","year":"2013","journal-title":"Br Med Bull"},{"issue":"2","key":"10.1016\/j.xkme.2022.100504_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0046-8177(81)80103-7","article-title":"Morphologic and clinical correlates in renal amyloidosis","volume":"12","author":"Dikman","year":"1981","journal-title":"Hum Pathol"},{"key":"10.1016\/j.xkme.2022.100504_bib28","series-title":"Exploring New Findings on Amyloidosis","article-title":"Amyloid nephropathy: a practical diagnostic approach and review on pathogenesis","author":"Paueksakon","year":"2016"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","article-title":"A\u00a0comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue","volume":"68","author":"Gilbertson","year":"2015","journal-title":"J\u00a0Clin Pathol"},{"issue":"6","key":"10.1016\/j.xkme.2022.100504_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10067-003-0763-9","article-title":"Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis","volume":"22","author":"Nakamura","year":"2003","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.xkme.2022.100504_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.xkme.2022.100504_bib32","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1093\/rheumatology\/kes190","article-title":"Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis","volume":"51","author":"Nakamura","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.xkme.2022.100504_bib33","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00296-008-0590-z","article-title":"A\u00a0case of AA amyloidosis associated with rheumatoid arthritis effectively treated with infliximab","volume":"28","author":"Kuroda","year":"2008","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib34","first-page":"404","article-title":"Treatment with adalimumab in amyloidosis secondary to rheumatoid arthritis: two case reports","volume":"33","author":"Fikri-Benbrahim","year":"2013","journal-title":"Nefrologia"},{"issue":"34","key":"10.1016\/j.xkme.2022.100504_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007859","article-title":"Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: a STROBE-compliant observational study","volume":"96","author":"Esatoglu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib36","first-page":"431","article-title":"Familial Mediterranean fever (FMF) and renal AA amyloidosis--phenotype-genotype correlation, treatment and prognosis","volume":"16","author":"Ben-Chetrit","year":"2003","journal-title":"J\u00a0Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib37","first-page":"1299","article-title":"Familial Mediterranean fever-associated renal amyloidosis: case report and review of the literature","volume":"60","author":"Andronesi","year":"2019","journal-title":"Rom J Morphol Embryol"},{"issue":"12","key":"10.1016\/j.xkme.2022.100504_bib38","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/art.1780371215","article-title":"Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome","volume":"37","author":"Livneh","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine--update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13075-017-1434-6","article-title":"A\u00a0new bioassay for measuring the strength of IL-6\/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis","volume":"19","author":"Saito","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"6 suppl 94","key":"10.1016\/j.xkme.2022.100504_bib41","first-page":"S46","article-title":"Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature","volume":"33","author":"Lane","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.xkme.2022.100504_bib42","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/art.22118","article-title":"Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis","volume":"54","author":"Okuda","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/13506129.2011.613962","article-title":"Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis","volume":"18","author":"Magro-Checa","year":"2011","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.xkme.2022.100504_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/13506129.2014.1002031","article-title":"AA amyloidosis treated with tocilizumab: case series and updated literature review","volume":"22","author":"Courties","year":"2015","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/RHU.0b013e318293793c","article-title":"Renal amyloidosis secondary to rheumatoid arthritis: remission of proteinuria and renal function improvement with tocilizumab","volume":"19","author":"Vinicki","year":"2013","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.xkme.2022.100504_bib46","article-title":"Therapeutic benefits of tocilizumab vary in different organs of a patient with AA amyloidosis","volume":"2014","author":"Matsui","year":"2014","journal-title":"Case Rep Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2022.100504_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s13730-014-0127-0","article-title":"Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis","volume":"3","author":"Yamada","year":"2014","journal-title":"CEN Case Rep"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/14397595.2013.874748","article-title":"Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis","volume":"25","author":"Iijima","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12882-017-0799-8","article-title":"Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report","volume":"18","author":"Yamagata","year":"2017","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5414\/CN109971","article-title":"Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: two case reports","volume":"95","author":"Fukuda","year":"2021","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2013.854048","article-title":"Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases","volume":"24","author":"Okuda","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.xkme.2022.100504_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/14397595.2018.1515145","article-title":"AA amyloidosis - benefits and prospects of IL-6 inhibitors","volume":"29","author":"Okuda","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"6 suppl 94","key":"10.1016\/j.xkme.2022.100504_bib53","first-page":"S169","article-title":"Remission of nephrotic syndrome due to AA-amyloidosis, complicating familiar Mediterranean fever, with tocilizumab","volume":"33","author":"Serelis","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13023-017-0642-0","article-title":"Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial Mediterranean fever","volume":"12","author":"Ugurlu","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.xkme.2022.100504_bib55","first-page":"178","article-title":"Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis","volume":"4","author":"De La Torre","year":"2011","journal-title":"NDT Plus"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/13506129.2013.838947","article-title":"AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab","volume":"20","author":"Ho\u010devar","year":"2013","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.xkme.2022.100504_bib57","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/0886022X.2013.773913","article-title":"Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet\u2019s disease","volume":"35","author":"Redondo-Pach\u00f3n","year":"2013","journal-title":"Ren Fail"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2022.100504_bib58","doi-asserted-by":"crossref","first-page":"i398","DOI":"10.1093\/ndt\/gfw185.63","article-title":"MP172 Tocilizumab treatment for nephrotic syndrome due to secondary amyloidosis in rheumatic and inflammatory diseases","volume":"31","author":"Cabello Pelegrin","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2022.100504_bib59","article-title":"Successful treatment of AA amyloidosis in ankylosing spondylitis using tocilizumab: report of two cases and review of the literature","volume":"8","author":"Eriksson","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.xkme.2022.100504_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s13730-020-00507-4","article-title":"Use of tocilizumab in amyloid a nephropathy associated with Sweet syndrome: a case report and literature review","volume":"10","author":"Giannese","year":"2021","journal-title":"CEN Case Rep"},{"issue":"23","key":"10.1016\/j.xkme.2022.100504_bib61","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa065644","article-title":"Eprodisate for the treatment of renal disease in AA amyloidosis","volume":"356","author":"Dember","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xkme.2022.100504_bib62","first-page":"37","article-title":"Review of eprodisate for the treatment of renal disease in AA amyloidosis","volume":"5","author":"Rumjon","year":"2012","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.xkme.2022.100504_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fimmu.2011.00032","article-title":"Generation and characterization of anti-AA amyloid-specific monoclonal antibodies","volume":"2","author":"Wall","year":"2011","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.xkme.2022.100504_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141330","article-title":"Discovery and characterization of a potent interleukin-6 binding peptide with neutralizing activity in\u00a0vivo","volume":"10","author":"Ranganath","year":"2015","journal-title":"PLoS One"},{"issue":"407","key":"10.1016\/j.xkme.2022.100504_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7621","article-title":"Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients","volume":"9","author":"Schonhoft","year":"2017","journal-title":"Sci Transl Med"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952200125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952200125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:23:43Z","timestamp":1762910623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259005952200125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S259005952200125X"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2022.100504","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Amyloid A Protein\u2013Associated Kidney Disease: Presentation, Diagnosis, and Management","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2022.100504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100504"}}